Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -25.65M | -26.69M | -22.27M | -19.04M | -18.35M |
| Total Depreciation and Amortization | 137.00K | 149.00K | 148.00K | 142.00K | 135.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.85M | 6.04M | 659.00K | -2.86M | -3.09M |
| Change in Net Operating Assets | 726.00K | 1.71M | 3.63M | 3.48M | 2.31M |
| Cash from Operations | -16.94M | -18.79M | -17.83M | -18.27M | -19.00M |
| Capital Expenditure | -1.00K | -57.00K | -186.00K | -194.00K | -202.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.00K | -57.00K | -186.00K | -194.00K | -202.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -67.00K | -67.00K | -67.00K | -20.00K | -75.00K |
| Issuance of Common Stock | 5.56M | 5.62M | 1.90M | 2.22M | 2.22M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1.52M | -1.52M | -1.52M | -1.52M |
| Cash from Financing | 5.50M | 4.03M | 317.00K | 680.00K | 625.00K |
| Foreign Exchange rate Adjustments | -132.00K | 67.00K | 39.00K | -36.00K | -33.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.57M | -14.75M | -17.66M | -17.82M | -18.61M |